Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

HER2 signaling can also promote cell survival and colonization at distant metastatic sites, establishing secondary tumors. HER2-positive tumors have different clinicopathological features and ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

"Patients with HER2-positive metastatic breast cancer often ... "With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined ...

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.